NeuBase Therapeutics Inc expected to post a loss of 11 cents a share - Earnings Preview

NeuBase Therapeutics

08/05/2023 12:53

* NeuBase Therapeutics Inc  NBSE.OQ   NBSE.O  is expected
to show
no change in quarterly revenue when it reports  results on May
10 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for NeuBase
Therapeutics Inc
is for a loss of 11 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for NeuBase
Therapeutics Inc is $7​, above​ its last closing price of $0.18.
​​​

This summary was machine generated May 8 at 11:53 GMT.  All
figures in US dollars  unless otherwise stated